TW203012B - - Google Patents

Download PDF

Info

Publication number
TW203012B
TW203012B TW080105605A TW80105605A TW203012B TW 203012 B TW203012 B TW 203012B TW 080105605 A TW080105605 A TW 080105605A TW 80105605 A TW80105605 A TW 80105605A TW 203012 B TW203012 B TW 203012B
Authority
TW
Taiwan
Prior art keywords
percent
desirably
item
composition
oil
Prior art date
Application number
TW080105605A
Other languages
Chinese (zh)
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Application granted granted Critical
Publication of TW203012B publication Critical patent/TW203012B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

203012 A6 B6 五、發明説明(1 本發明相闋於固釀藥用組成物及其製法。更待定而言 ,本發明相Μ於含有一種可灌擇性地溶於水的感光性有效 成分的固髖藥用組成物,此外,尚相關於此種組成物之製 備方法。 含有以感光性物霣為有效成分的蕖用組成物的製備具 有嚴重的困難,為人所共知。在光的作用下,形成了分解 生成物,就治療的觀黏來看,可能是_物失去效力、甚且 對人體有害。同時,藥典規範對於分解生成物也有日益嚴 苛的要求。不能夠即溶於水的有效成分只有在克服了很大 的困難的情況下才能配製,逭一»亦為人知。一方面,不 能夠溶於水的成分幾乎不能溶於用以製備藥用組成物的載 剤及添加劑中,另一方面,用於分子的不良水溶性,有效 成分的釋出為輕微程度。 從以上的事寅可知,将想光性以及幾乎不溶於水的有 效成分配方纳入固體_用組成中對於精練的技術人員而言 是一項困難的工作,同時,對於製藥工業而言,其需求也 曰益緊迫。 上述問醣待別發生在以二氲吡啶衍生物製迪藥物製備 上,二氫吡啶衍生物既是感光性的,同時也幾乎不能溶於 水。逭類化合物中最具重要代表性的之一躭是nifedipine (即:4-(2’-硝基苯基)-2,6-二甲基-3,5-二甲氣基羰基 -1,4-二氬吡啶),它是一種廣泛使用的鈣對抗物(calc iu· antagonist),在治療急性與慢性局部貧血性心臓疾病, 离血颳,腦部及末稍循環失常等病症上非常有用。 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) 請 先 聞 讀 背 面 之 注· 意 事· 項- 再 填 寫 页 經濟部中央搮準局貝工消費合作杜印製 A6 B6 203012 五、發明説明(2 請 先 閲 讀 背 之 注* 意 事_ 項- 再 填 寫 本 页203012 A6 B6 V. Description of the invention (1 The present invention is based on the solid brewing pharmaceutical composition and its preparation method. More to be determined, the present invention contains a photosensitive active ingredient that is selectively soluble in water The pharmaceutical composition for fixing hips is also related to the preparation method of such a composition. The preparation of a composition for the use of a lotus containing a photosensitive substance as an active ingredient has serious difficulties and is well known. Under the action, decomposition products are formed. From the point of view of treatment, it may be that the substance loses its effectiveness and is even harmful to the human body. At the same time, the Pharmacopoeia regulations also have increasingly stringent requirements for decomposition products. It cannot be dissolved immediately. The active ingredients of water can only be formulated after overcoming great difficulties, and Yiyi »is also known. On the one hand, the ingredients that are insoluble in water are hardly soluble in the carrier and used to prepare the pharmaceutical composition and Among the additives, on the other hand, the poor water solubility of the molecule is used, and the release of the active ingredient is slight. From the above matter, it can be seen that the photoactive and almost insoluble active ingredient formula is included in the solid _ It is a difficult task for the skilled technicians to use the composition, and at the same time, the demand for the pharmaceutical industry is also urgent. The above question will not happen in the preparation of didipyridine derivatives. On the other hand, the dihydropyridine derivatives are both photosensitive and almost insoluble in water. One of the most important representative of the Japanese compounds is nifedipine (ie: 4- (2'-nitrophenyl)- 2,6-dimethyl-3,5-dimethylaminocarbonyl-1,4-dihydropyridine), which is a widely used calcium antagonist (calc iu · antagonist), in the treatment of acute and chronic local anemia Cardiovascular disease, blood squeegee, brain and peripheral dysfunction are very useful. This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210x297 mm). Please read the notes on the back side. Item-Fill in the page again A6 B6 203012 produced by Beigong Consumer Cooperation of the Central Bureau of Economics and Trade of the Ministry of Economic Affairs V. Description of invention (2 Please read the note on the back * Intention _ item-then fill in this page

Nifedipine的离度感光性及不易溶於水的現象已為 人知(參閲英國専利案説明窨第1,362,627 由於逭種 化合物分子的高度感光性,分解生成物-特別是硝基衍生 物與亞硝基衍生物-非常容易形成。分解生成物的最大容 許置是由幾種藥典規範決定的。依照美囲藥典第二十二版 (USP XXII)的規定,硝基化合物的最大容許量不得超過 2.0X (以霣量計),而亞硝基化合物之最大容許量不得超過 0.5Χ (以質量計)。此外,由於其在水中的難溶性, nifedipine不能夠容易地溶解於通常使用於製_工業以裂 備固體蕖用組成物的載劑與輔肋劑中,同時,由於其幾乎 不溶解於水,其有效成分的釋出程度非常低,因而使得適 當的吸收受阻。 經濟部中央樣準局員工消费合作社印製 含有nifedipine的蕖用組成物的合意的代表是軟膠 囊,但是由於其有效成分的感光性及微量的水溶性使得其 製備産生困難。人們已經發表了幾種製迪逭類軟0囊的方 法。依照英國專利案第1,362,627號説明害,將一種或多 種遮光劑(例如:二氣化鈦或磺酸鈣)以及選擇性地一種吸 收某®波長範園的光的合成染料(例如:Gelb〇range, Erythrosin)混入隳囊的毅中。遮光_的使用是不可少的 ,而合成染料的使用則只是可苗擇的。有色遮光則-例如 :氣化鏃顔料-讓醪囊殼産生令人喜愛的外觀及色彩。上 述有色顔料是以百分之二至三質量的量混入®囊的殼以確 保所補的抗楢色以效力。遮光剤的用量可以由添加一種染 料至組成物中而減至大約百分之0.5至1.5 (以質量計),但 本紙張尺度適用中國國家標準(CNS)甲4規格(210X297公釐) ^〇3〇ia A6 _____B6 五 '發明説明(3 ) 是其加入則是不可省略的。合成染料的本身不能確保逋成 绝對可靠的抗褪色效力,只有與邃光_一同使用時才可。 但是,利用隳囊壁逢成的防光侵》方式有鼹重的缺陷 。也就是,只有邸可使用的謬囊具有抗楢色效力,道種膠 囊早已包含了含有有效成分的《充溶液。而此有效成分在 製造以及裝埔過程中完全不能防止光的侵襲,因此,必須 實施痛要精密技術與努工紀律的昂資繁瑣的預防措施,以 避免因光産生的分解作用(例如:必須在不生膨響的红光 照射下作業等)。遇濾準備好了的溶液時,防止填充溶液 受到光效窿的侵襲待別重要。在灌裝謬囊的毎偏作樂步》 中,必須確保防止光侵襲(例如:利用黑色薄膜,阻光的 待殊裝置、光檷等)。 利用醪囊壁防止光授襲的S—項缺貼為:將細分的分 散固體遮光劑混入膠囊壁痛要施行分離作業及分離設備。 細微的粉狀遮光劑必須均匀地散佈在構成_囊壁的黏拥謬 質物料中,逭是一傾冗長又繁瑣的過程。在製造遇程中, 意外的不均勻性的發生可能性是不可排除的•醪質物料在 携拌時可能起泡,於是發生了異體包留物的形成·逭些異 醴包留物會産生不均勻性,並且存留於驩囊壁内。 經濟部中央標-f-局員工消费合作社印製 {請先M讀背面之ii-意Ϋ.ίιί-再填寫本贸) 已經公告的歐洲専利申謫案第143,857號掲示了含有 以nifedipine作為有效成分的軟騵囊。此種B囊壁含有 丙三醇(甘油),一種或多種吸收所欲波長範園的染料,及 一遮光劑,而構成騮囊装《物的混合物則含有溶於有機溶 劑中的nifedipine溶液。此専利申讅案的恃撖為謬囊装 ____ 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) A6 B6 203012 五、發明説明(4 填物含有nifedipine及溶於由聚醚酵溶在四氫糠酵(四氫 呋喃甲酵)所成的溶液中的聚乙烯基吡咯烷钃(PVP),且完 全不含丙三酵,丙三酵只存在於騵囊壁中。道種方法也有 上述的缺點,就是,將遮光_單獼地混入驥囊壁材料中, 因之,在製迪及裝埔作業中謬囊的裝熇物並未對光的照射 作預防,此外,上述之將速光薄混入謬囊壁時發生的困難 也箱克胆。 本發明的目的為耋力逹成一種製備固醱蕖用組成物的 簡單方法,逭種藥用组成物含有可S擇性地嫌乎不溶於水 的感光性物質為有效成分,此方法可確保達成可倍«丨的防 止光的侵襄,且消除迄今已知方法的缺黏。 本發明的目的特別提供一種易於實行的方法,保証達 成防止光的授襲,以製備含有感光性及稍微溶於水作為有 效成分的nifedipine的固鼸_用組成物-特別是軟騮囊。 本發明為基於在沒有遮光剤成分存在下時植物性染料 本身可以防止感光性有效成分進行光解的認知。 依據本發明之特歡,本發明提供一種製備含有感光性 及選擇性地幾乎不溶於水的有效成分與習用的載劑及/或 輔助劑的固醱藥用組成物的方法,此方法包括將植物性染 料混入組成物中。 就植物性染料而言,可合意地使用藥嫌素、焦糖、番 红花黃(藏红花黃)或甜菜根染料(Rote Beete· Dragocoo)。 依照本發明方法之合意形式或實際了解,最好是使用 綠色植物的天然染料-藥》素。 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) 請 先 閱 面 之 注 意 事 項 再 填 寫 本 页 經濟部中央標準局員工消费合作社印製 <i〇3〇l2The sensitivity of Nifedipine ’s sensitivity to light and its insolubility in water are well known (refer to the description of the British government case No. 1,362,627. Due to the high sensitivity of the molecules of the compound, the decomposition products-especially nitro derivatives and nitroso Derivatives-Very easy to form. The maximum allowable placement of decomposition products is determined by several pharmacopoeia specifications. According to the US Twenty-Second Edition (USP XXII), the maximum allowable amount of nitro compounds must not exceed 2.0X (In terms of amount), and the maximum allowable amount of nitroso compounds should not exceed 0.5Χ (in terms of mass). In addition, due to its poor solubility in water, nifedipine cannot be easily dissolved in the commonly used _industrial In the carrier and auxiliary rib agent of the solid preparation component, the release rate of its active ingredients is very low because it is almost insoluble in water, which hinders proper absorption. The preferred representative of the printing composition containing nifedipine from the consumer cooperative is a soft capsule, but due to the sensitivity of its active ingredients and the trace water solubility Difficulties have arisen. Several methods have been published for the preparation of Di-Yo soft capsules. According to the description of British Patent No. 1,362,627, one or more opacifiers (such as titanium dioxide or calcium sulfonate) and selectivity A synthetic dye (for example, Gelborange, Erythrosin) that absorbs light from a certain wavelength range is mixed into the bladder's perseverance. The use of shading is indispensable, and the use of synthetic dyes is only selective. Colored shading-for example: vaporized yoke pigments-gives the mash capsule shell a pleasing appearance and color. The above-mentioned colored pigments are mixed into the shell of the ® capsule in an amount of 2 to 3% by mass to ensure the supplement of the anti-slip The amount of shading can be reduced by adding a dye to the composition to about 0.5 to 1.5 percent (by mass), but this paper scale is applicable to China National Standard (CNS) A 4 specifications (210X297 Cli) ^ 〇3〇ia A6 _____B6 Five'Instructions for the invention (3) It can not be omitted if it is added. The synthetic dye itself cannot ensure an absolutely reliable anti-fading effect, only when used together with 邃 光 _ Yes, but The method of using the anti-light intrusion on the wall of the capsule is flawed. That is, only the pouches that can be used by Di have anti-color effects. Dao capsules already contain "filling solution containing active ingredients. And this The active ingredients cannot completely prevent the invasion of light during the manufacturing and installation process. Therefore, it is necessary to implement expensive and cumbersome preventive measures that require precise technology and labor discipline to avoid the decomposition caused by light (for example: Working under the irradiated red light, etc.). In the case of filtering the prepared solution, it is important to prevent the filling solution from being attacked by the light effect. In the case of filling the pouch, it must be ensured to prevent Light attack (for example: use of black film, special device for blocking light, light filter, etc.). The lack of S-item that uses the wall of the mash sac to prevent photoinfestation is: mixing subdivided dispersed solid sunscreen into the capsule wall and performing separation operations and separation equipment. The fine powdered sunscreen must be evenly distributed in the sticky material that constitutes the _ capsule wall, which is a long and cumbersome process. During the manufacturing process, the possibility of accidental non-uniformity is unavoidable. • Mash materials may blister when carried and mixed, so the formation of foreign body inclusions occurs. In case of some heterogeneous residues, Non-uniformity, and it remains in the wall of Huan Huan. Printed by the Central Standard of the Ministry of Economic Affairs-f-bureau employee consumer cooperatives (please read the second ii-Ii.Io.-then fill in this trade). The already announced European Patent Application No. 143,857 shows that it contains nifedipine as effective Ingredients in soft sacs. This type of B capsule wall contains glycerol (glycerol), one or more dyes that absorb the desired wavelength range, and a sunscreen agent, and the mixture that constitutes the contents of the sacral capsule contains nifedipine solution dissolved in an organic solvent. The complaint in this case is a false pack ____ The paper size is in accordance with Chinese National Standard (CNS) A 4 specifications (210x297 mm) A6 B6 203012 V. Description of invention (4 The filling contains nifedipine and is soluble in polymer Ether fermentation is dissolved in a solution of tetrahydrofuran fermentation (tetrahydrofuran methyl fermentation) polyvinylpyrrolidine strontium (PVP), and it is completely free of glycerol fermentation, which only exists in the wall of the sac. The method also has the above-mentioned shortcomings, that is, the shading_single kiwi is mixed into the material of the wall of the bladder, so that the decoration of the bladder in the production of Di and Zhuangpu does not prevent the irradiation of light. The difficulty that occurs when mixing the fast light thin into the wall of the bladder is also stubborn. The purpose of the present invention is to create a simple method for preparing a composition for solid hydration, and the medicinal composition contains optional Photosensitive substances that are considered to be insoluble in water are effective ingredients. This method can ensure that it can achieve twice the prevention of light intrusion and eliminate the lack of stickiness of the previously known methods. The purpose of the present invention is to provide an easy-to-implement Method to ensure the prevention of light attack to prepare A solid composition for nifedipine containing photosensitivity and slightly soluble in water as an active ingredient-especially soft sac. The present invention is based on the fact that the plant dye itself can prevent the photosensitive active ingredient from proceeding in the absence of a shading ingredient Cognition of photolysis According to the special joy of the present invention, the present invention provides a method for preparing a solid pharmaceutical composition containing an active ingredient that is photosensitive and selectively hardly soluble in water and a conventional carrier and / or adjuvant This method includes mixing vegetable dyes into the composition. As for vegetable dyes, it is desirable to use pharmacokinetics, caramel, saffron yellow (saffron yellow) or beetroot dye (Rote Beete · Dragocoo). According to the desired form or actual understanding of the method of the present invention, it is best to use the natural dye-pharmaceuticals of green plants. This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210x297 mm). Please read the precautions first. Refill this page Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy < i〇3〇l2

A B 五、發明説明(5 ) 親脂型與親水型葉錄素二者皆適於以所想要的结果來 逹成本發明方法。親脂型窠綠素是以有機溶劑自奪賻萃取 而得。’親脂型葉緣素為一種深綠色蜂蜜狀物質。親水型藥 緣素為一種天然來源的染料,其分子之中央iM原子被換成 錮原子後,其水榕性的納鹽可為與氫氣化納作用而得。押 鹽則可以類似方法與氫氣化押作用而製得。親水型藥嫌素 為一種細微分敗的嫌色粉末。 植物性染料之用*可依生成物總質量的百分之0.1至 10的霣董使用。 依據吾人的經驗,下列趣擇性地幾乎不溶於水的感光 性化合物可用以裂備依本發明之固«藥用組成物之有效成 分: 維生索丁,合意地是油菜0化酵(維生素丁二· Dd; 請 先 聞 面 < i 事 項 再 填 % 本 页 經濟部中央棵準局貝工消费合作社印製 維生素甲; 咪唑啉(間二氰雜琛戊烯)衍生物,合意的是lethynazol 哌矂(對二氰己璨)衍生物,合意的JStripolydine hydrazine hydrochloride; 麥角雉與吲嵘殮,合意的是甲基礒酸二氫麥角毒或酒 石酸麥角胺; 丁睡苯衍生物,合意的是haloperidol· droperidol 或 benper i do 1 ; 硝化甘油; 二氫%徒衍生物,合意的是nifedipine, nirudipine, nitrendipine, nisoldipine, niaodipine, nicarbipine 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) 經濟部中央標準局員工消费合作社印製 2〇3⑽ 五、發明說明(6 ) 或 phenodipine; 組成類固酵,合_意的是phenoxynesteron; 甲狀腺荷爾鲮,合意的是左旋甲狀腺胺酸(左旋甲狀 腺素); 葉酸類似物的抗代謝物,合意的是Bethotrexate; _脸類似物的抗代謝物,合意的是azathoprine; 硝基咲喃衍生物,合意的是nitrofurantoin; 抗新塑性 nethy 1 hydrox i nes ,合意的是 procarbaz ine ; 皮質類固酵(皮質甾),合意的是betanethasone; 亞硝基鐵氰化納(即,硝普酸納,硝普化納>; 嗎啡衍生物,合意的是硫酸喝琲,罂粟麯氫氰化物; 兒茶酚(即,笨鄰二酚),合意的是多巴(即,二羥基 苯丙按酸)或isoprenaline; 雌激素,合意的是己甾酵; 磺胺噠嗪; 瞼,合意的是秋水仙 P r 〇 f e η衍生物,合意的是k e t 〇 p r 〇 f e η ; 抗生素,合意的是分絲鯖抗徽索或桿菌肽: 三琛抗抑制W,合意的是carba*az:epine; 盼唾嗪(即,硫氮雜Μ),合意的是hibernal或三氟 通吖嗪: nustardnitrogens: 古柯_氳氰化物; 乙二胺衍生物,合意的是tripelenaiine:或 8 A6 B6 (請先閑讀背面之注意事項再填寫本頁) .裟. •打· •緣· 本纸張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) ^03012 經濟部中央標準局員工消费合作社印製 五、發明説明(7 胺基咬啉衍生物,合意的是chloroquine。 依照本發明的一項特別合意的具黼實例,一種幾乎不 溶於水的感光性二氫吡啶衍生物諸如維生素甲或硝化甘油 被用來作為有效成分。 依照本發明的另一項特別合意的具龌資例,在水中的 溶解度於鑷氏25度時不超遇20公克/公升的二氫吡啶衍生 物可用以作為有效成分。因此,nifedipine, niludipine nitrendipine, nisoldipine, niaodipine, nicardipine 及felodipUe均被証寅作為有效成分是待別合意的。 依據本發明方法,感光性及苗擇性地幾乎不溶於水的 有效成分可以被合意地配製進入軟腰囊、藥片、耱衣蕖九 或硬驪囊,特別是可配入軟顧囊。 當製備軟腰囊時,將一種植物性染料_待別是藥鐮素 -混入膠囊的裝熵物。因此,不止是在被封入驪囊後,在 製造及裝《遇程中.含有感光性有效成分的裝《物就已經 受到免於受光侵襲的保護了。利用埴種方法,可以免除在 製造包含了感光性有效成分裝《物時確保達成免於受光侵 襲的昂貴且繁瑣的方式。 親脂型葉綠素是以百分之1至10(以質麗計)的量混入 裝埔物中,合意的是百分之1至5 ,待別合意的是百分之 1.5至3.5。裝填物中的親水型》«的含量以質量計可介於 百分之0.5至10之間,合意的是百分之1至7之間,特別合 意的是百分之1.5至5之間。如果以nifed ip丨ne作為有效成 分,則裝填物中有效成分的含Μ以質Μ計可介於百分之〇. 請 先 閑 讀 背 之 注 意 事 項 再 填 页 本紙張尺度適用中國國家標準(CNS)甲4規格(210x29/公釐) 203012 A6 B6 經濟部中央樣準局員工消费合作杜印製 五、發明說明(8 ) 至7之間,合意的是百分之1至5之間,特別合意的是百分 之1.5至3之間。 就進一步的其他成分而言,裝瑱物也可含有適於供口 服使用及與軟謬囊壁材料相容的溶_。為此目的,可使用 . 下列溶劑:植物油及芳番油(諸如葵花油、葫蘆油、橄橛 油、檸嫌油等),非離子型表面活性劑(例如:聚(乙烯化 氧)-山梨糖酵酐脂肪酸酯,合意的是聚(乙烯化氣)-山梨 糖醇酐一油酸酯),卵磷酯或聚乙二酵(例如:Carbowax 300)。腰囊装《物也可理擇性地含有芳番_ (例如:番料 或香箱油)。 當使用親脂性藥綠素時,驥囊的装瑱物可含有的溶两 合意的是聚(乙烯化氣)-山梨耱酵酐脂肪酸酯,持別是 聚(乙烯化氣)-山梨耱酵酐-油酸酯。笛使用親水性蕖嫌 素時,最好是使用聚乙二酵(例如:Carbowax 300)為溶劑。 繆囊裝熵物的製備是以製麵工樂上的習用方法實施。 合意地是將有效成分溶於加熱至某適宜溫度的溶劑中進行 。親脂性葉錄素或親水性葉嫌素以及其他成分可於此溶液 仍是熱的時候加入,也可於冷卻以後加入,如有必要,將 如此所得之溶液於一篩網上過濾。 然後將以上述方法製備的含有植物性染料的裝《物注 入軟腰囊。謬囊壁可含有明驥基質增塑劑(例如:甘油或 山梨糖酵)及防腐劑(例如:對羥苯酸甲酯,俗名:尼杷晉, Hipagin)。也可以将植物性染料-合意的是葉嫌素-加入 驥囊壁的材料中。在道種埸合時,隳囊壁的藥嫌素含量以 (請先閱讀背面之>i-意事項再填寫本頁) •St. .打· •線· 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐)A B 5. Description of the invention (5) Both lipophilic and hydrophilic phytohormones are suitable for carrying out the invention method with the desired results. The lipophilic berberine is derived from organic solvents. The lipophilic phyllocyanin is a dark green honey-like substance. Hydrophilic pheromone is a dye of natural origin. After the central iM atom of the molecule is replaced with a sulfur atom, its water-containing sodium salt can be obtained by reacting with hydrogen hydride. The salt can be prepared in a similar way with hydrogen gas desulfurization. The hydrophilic drug is a kind of fine color powder. The use of vegetable dyes * can be used according to 0.1 to 10 percent of the total mass of the product. According to my experience, the following interesting photosensitive compounds that are almost insoluble in water can be used to prepare the active ingredients of the solid «pharmaceutical composition according to the present invention: Vitamin Sardine, desirably rapeseed 0 (fertility) Ding Er · Dd; Please listen to the face < i matters and fill in% This page is printed by the Ministry of Economic Affairs, Central Bureau of Industry and Fisheries Consumer Cooperatives of Vitamin A; imidazoline (m-dicyanopentapentene) derivatives, it is desirable lethynazol piperazine (p-dicyanohexyl) derivative, desirable JStripolydine hydrazine hydrochloride; ergot pheasant and indole mortar, desirably methyl hydrogen dihydroergotoxine or ergotamine tartrate; butylbenzene derivatives , Desirable is haloperidol · droperidol or benper i do 1; Nitroglycerin; Derivatives of dihydrogen%, Desirable is nifedipine, nirudipine, nitrendipine, nisoldipine, niaodipine, nicarbipine This paper scale is applicable to China National Standard (CNS) A4 (210x297mm) Printed by employees' consumer cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 2〇3⑽ V. Description of invention (6) or phenodipine; composed of solid fermented yeast, which means ph enoxynesteron; thyroid hormone carp, desirably levothyroxine (levothyroxine); antimetabolites of folic acid analogs, desirably Bethotrexate; _ antimetabolites of face analogs, desirably azathoprine; nitroso Derivatives of furan, desirably nitrofurantoin; anti-neoplasticity nethy 1 hydrox i nes, desirably procarbaz ine; corticosteroids (corticosteroids), desirably betanethasone; nitroso ferricyanide (ie, nitroprusside Sodium acid, nitroprusside> morphine derivatives, desirably sulphuric acid drink, poppy koji hydrocyanide; catechol (i.e., catechol), desirably dopa (i.e., dihydroxybenzene Propionic acid) or isoprenaline; estrogen, desirably hexyl sterase; sulfapyridazine; eyelid, desirably colchicine Pr 〇fe η derivatives, desirably ket 〇pr 〇fe η; antibiotics, desirably It is a split mackerel anti-Huiso or Bacitracin: Sanchen anti-inhibits W, desirably carba * az: epine; hope siazine (ie, thiodiazepine M), desirably hibernal or trifluorotonazine: nustardnitrogens : Coca_Cyanide; B Amine derivatives, tripelenaiine is desirable: or 8 A6 B6 (please read the precautions on the back before filling in this page). 裟. • Hitting • • Edges • This paper size applies to China National Standards (CNS) A4 specifications (210x297 mm) ^ 03012 Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of the invention (7 Aminobitoline derivatives, chloroquine is desirable. According to a particularly desirable embodiment of the present invention, a photosensitive dihydropyridine derivative such as vitamin A or nitroglycerin, which is almost insoluble in water, is used as an active ingredient. According to another particularly favorable example of the present invention, a dihydropyridine derivative whose solubility in water does not exceed 20 g / L at 25 ° C can be used as an active ingredient. Therefore, it is undesirable that nifedipine, niludipine nitrendipine, nisoldipine, niaodipine, nicardipine and felodipUe are all recognized as effective ingredients by Zheng Yin. According to the method of the present invention, the photosensitive and selective selective water-insoluble active ingredients can be desirably formulated into soft waist pouches, tablets, Chiao Jiu Jiu, or hard bladders, especially soft pouches. When preparing a soft lumbar sac, a plant dye, to be treated as a medicine, is mixed into the entropy of the capsule. Therefore, it is not only after being enclosed in the bursa, but also in the manufacture and installation of the package. The package containing the photosensitive active ingredient has already been protected from light. This method can eliminate the costly and cumbersome way of ensuring protection from light when manufacturing articles containing photosensitive active ingredients. The lipophilic chlorophyll is blended into Zhuangpu in an amount of 1 to 10% (in terms of quality), the desired amount is 1 to 5%, and the undesirable amount is 1.5 to 3.5%. The content of "hydrophilic type" in the filling can be between 0.5 and 10 percent by mass, desirably between 1 and 7 percent, and particularly preferably between 1.5 and 5 percent. If nifed ip 丨 ne is used as the active ingredient, the content of the active ingredient in the filling can be between 0% and 0%. Please read the precautions carefully before filling this page. The paper size is applicable to the Chinese national standard ( CNS) A4 specifications (210x29 / mm) 203012 A6 B6 Central Ministry of Economic Affairs Bureau of the Central Bureau of Samples and Consumers' cooperation in printing du. Fifth, the description of invention (8) to 7, between 1 and 5 percent is desirable, Particularly agreeable is between 1.5 and 3 percent. With regard to further other ingredients, the container may also contain a solution suitable for oral use and compatible with the soft wall material. For this purpose, the following solvents can be used. Vegetable oils and aromatic oils (such as sunflower oil, gourd oil, olive oil, lime oil, etc.), non-ionic surfactants (for example: poly (ethylene oxide) -Sorbus Glycolic acid esters of fatty acids, desirably poly (ethylene gas) -sorbitan monooleate), lecithin or polyethylene glycol (eg Carbowax 300). The lumbar pouches can also optionally contain Fang Fan_ (for example, fan material or incense box oil). When using lipophilic medicine chlorophyll, the contents of the capsule can contain poly (ethylene oxide) -sorbic acid fatty acid ester, and poly (ethylene oxide) -sorbic acid. Anhydride-oleate. When the flute uses hydrophilic metabolites, it is best to use polyethylene glycol (eg Carbowax 300) as the solvent. The preparation of the entropy of Miao capsules is carried out by the conventional method of noodle making music. It is desirable to dissolve the active ingredient in a solvent heated to a suitable temperature. The lipophilic phytohormones or hydrophilic phytohormones and other components can be added while the solution is still hot, or after cooling, and if necessary, filtering the solution thus obtained on a screen. Then, the preparation containing the vegetable dye prepared by the above method is injected into the soft waist pouch. The wall of the absurd sac may contain a Mingji matrix plasticizer (for example: glycerin or sorbose) and a preservative (for example: methyl paraben, common name: Nipajin, Hipagin). It is also possible to add a plant dye-desirably phytoxanthin-to the material of the cyst wall. At the time of the combination of Dao species, the content of pharmacokinetics in the wall of the capsule is as follows (please read the "i-Importance" on the back and then fill out this page) CNS) A4 specifications (210x297 mm)

6 6 A B ^03012 五、發明説明(9 ) {請先閑讀背面之:¾意事ifi·再填寫本页) 質董計為百分之0.1至5,合意的是百分之0.2至3,待別合 意的是百分之0.3至1.5。騙囊壁也可含有親水型的窠鐮素。 含有植物性染料的驥囊壁的製備以如下方法施行:將 增塑劑(例如:丙三醇(甘油)或山梨糖酵)及S擇性地施加 的其他成分(例如:聚乙烯基吡咯烷酮或一種防腐W)溶於 溫水(攝氏70度至90度),再將明驥加入此溶液。將如此_ 得的物質在真空下於連續激烈地》拌下處理,直至其形成 一種半透明的蛛蜜狀物霣為止。先將葉綠素單獼地溶在少 量的水中,然後再與已經製成且冷卻的前述蜂蜜狀物霣柑 混合。 謬囊的灌製成形是以就其本身而論的已知方法以檐械 加工來實施的。第Η、糖衣蕖九及硬B囊可含有下列習用 的載劑及/或輔肋劑: 經濟部中央標準局員工消費合作杜印製 分散剤:諸如澱粉、改質澱粉、纖維素、繼維素衍生 物、交聯聚乙烯丙烯(PVPP),藻朊酸納及騵化二氣化矽; 黏合劑如:明腰、黃蕃騵、葡萄耱糖漿、澱粉、聚乙烯丙 烯、鑛維素衍生物、聚乙二酵(PEG 1000-5000)及薄朊酸 鹽;潤滑劑如:硬脂酸纟ϋ、硬脂酸、石蠟、滑石、植物或 動物脂肪、油及播、矽酗、聚乙二醇(例如PEG 1000-5000) ;載剤及填充料如··澱粉、繼維素、聚乙烯丙烯、交嫌聚 乙烯丙烯、膠化二氣化矽、乳糖、硬脂酸錤、硬脂酸鈣; 稀轉劑如:乳糖、甘露糖酵、澱粉、微晶纖維素;著色_ 及芳香劑及習用塗覆物。 上述固驩藥用組成物之藥九可含有以質量計為百分之 _11_ 本紙張尺度適用中國國家標準(CNS)中4規格(210x297公釐) A6 B6 ^03013 五、發明説明(10 ) 0.1至5之植物性染料,合意的是百分之0.5至3,而其塗覆 物可含有以質量計為百分之0.1至1,合意地是百分之0.3 至0.7的相同物質。 依本發明的藥片、糖衣藥九及硬願囊的裂備是以就其 本身而諭的已知方法實施。 依照本發明的另一項特微,提供一種含有灌擇性地幾 乎不溶於水的感光性有效成分以及習用載_及/或_肋_ 的固釀_用組成物,其中所述之組成物含有植物性染料。 依本發明的固讎藥用组成物的合意形式、植物性染料 、以及合意地使用於依本發明的固«藥用組成物中的感光 性及幾乎不溶於水的有效成分已載明如上。 依照本發明之一合意待擻,提供含有nifedipine為有 效成分之_用組成物-待別是軟騵囊。 依照本發明之S —項待擻,提供含有nifedipine為有 效成分之軟膠囊,其中之裝«物及/或騮囊壁混有植物性 染料,最好是蕖嫌素,其悬為以質量計佔百分之0.1至10。 依照本發明之軟謬囊有效成分之光解分解作用你歷經 四小時之所謂”日照試驗"而予以探究。其结果列於表一。 請 先 閱 面 之 注 意 事 項 再 填 寫 本 页 經濟部中央樣準局貝工消費合作杜印製 表 使用試樣 實例编號 光解分解作用 有效成分之最初《度 (以質量計之百分率) % 12 分解生成物之«度 (以質量計之百分率> % 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) 203012 Α (ί Π 66 6 AB ^ 03012 V. Description of the invention (9) {Please read the back of the page: ¾Isif ifi · Fill in this page) The quality manager counts as 0.1 to 5 percent, and the desired is 0.2 to 3 percent It is 0.3 to 1.5 percent to be unconvinced. The sac wall can also contain a hydrophilic fusarium. The preparation of the wall of the cysts containing vegetable dyes is carried out as follows: a plasticizer (for example: glycerol (glycerol) or sorbose) and other components (for example, polyvinylpyrrolidone or A kind of antiseptic W) dissolved in warm water (70 degrees to 90 degrees Celsius), and then added Ming Ji to this solution. The material thus obtained was continuously and vigorously stirred under vacuum until it formed a translucent spider honey. First dissolve chlorophyll kiwi in a small amount of water, and then mix it with the previously-made and cooled honey-like mandarin orange. The potting of the absurd pouch is carried out by eaves machining using a known method in its own right. The Η, sugar-coated Jiu Jiu and hard B capsules may contain the following customary carriers and / or auxiliary ribs: The Ministry of Economic Affairs Central Standards Bureau staff consumption cooperation du printing dispersions: such as starch, modified starch, cellulose, Jiwei Derivatives, cross-linked polyethylene propylene (PVPP), sodium alginate and zirconium dioxide gas binder; binders such as: Ming Yao, Huang Fan, grape syrup, starch, polyethylene propylene, ore derivation Substances, polyethylene glycol (PEG 1000-5000) and thin prionate; lubricants such as: stearic acid, stearic acid, paraffin, talc, vegetable or animal fats, oils and seeds, silicon alcohol, polyethylene Glycol (eg PEG 1000-5000); Carrier and fillers such as starch, Jiweisu, Polyethylene propylene, Polyethylene propylene, Gelatinized silicon dioxide, Lactose, Stearic acid, stearin Calcium acid; dilute conversion agents such as: lactose, mannose, starch, microcrystalline cellulose; coloring and fragrances and conventional coatings. The above-mentioned medicinal composition of Guhuan may contain 9% by mass _11_ This paper scale is applicable to the 4 specifications (210x297 mm) of China National Standards (CNS) A6 B6 ^ 03013 V. Description of the invention (10) A vegetable dye of 0.1 to 5 is desirably 0.5 to 3 percent, and its coating may contain the same substance as 0.1 to 1 percent by mass and desirably 0.3 to 0.7 percent. The splitting of the tablets, dragee 9 and hard capsule according to the present invention is carried out by a known method enacted by itself. According to another feature of the present invention, there is provided a composition for solid brewing containing a photosensitive active ingredient selectively hardly soluble in water and a conventional carrier_and / or_rib_, wherein the composition Contains vegetable dyes. Desirable forms of the solid pharmaceutical composition according to the present invention, vegetable dyes, and the active ingredients desirably used in the solid pharmaceutical composition according to the present invention and almost insoluble in water have been described above. According to one of the present invention, it is desirable to provide a composition containing nifedipine as an effective ingredient-to be a soft capsule. According to the S-item of the present invention, a soft capsule containing nifedipine as an active ingredient is provided, in which the contents and / or the wall of the sac sac are mixed with plant dyes, preferably metabolites, the suspension of which is based on mass It accounts for 0.1 to 10 percent. According to the photolysis decomposition effect of the active ingredients of the soft absurd pouch according to the present invention, you will explore it in the so-called "sunshine test" after four hours. The results are listed in Table 1. Please read the precautions before you fill in this page. The sample quasi-authorized shellfish consumer cooperation du printing watch uses the sample instance number. The initial "degree (percentage by mass) of the active ingredient of photolysis decomposition% 12" degree (percentage by mass>) of the decomposition product " % This paper scale is applicable to China National Standard (CNS) A 4 specifications (210x297 mm) 203012 Α (ί Π 6

五、發明説明(lD 81 -02-06 修正V. Description of the invention (lD 81 -02-06 amended

硝基 亞硝基 其他 装埔溶液: 實例二 醪囊壁: 實例四 98.50 1.00 0.23 0.27 裝埔溶掖: 實例一 驩囊壁: 實例五 98.00 0.90 0.24 0.86 比較實例 1.8 0.4 0.8 (請先閲讀背而之注意赛項#填寫本页) 經濟部屮央標準局EX工消费合作杜印製 依 解生成 合物之 知,依 量。值 料的軟 國藥典 躔光劑 令 適當的 照美國藥典第二十二販(USP XX II)之規定,硝基分 物之量以質蛋計不得超通百分之2.0,而亞硝基化 量以質量計不得超遇百分之0.5。由表一之數據可 本發明製備之軟騙囊含有之分解生成物逋低於容許 得离度注意的是:即使只在装填物中含有植物性染 膠囊,在騙囊壁中並無蓿色剤之混入,亦能滿足美 第二十二販之規定。另一方面,腰囊壁中不含任佝 人驚奇地發現,利用依本發明的方法不僅可以獲致 防止光的侵而且植物性染料也可增進nifedipine 13 私紙》尺度遑用t«國家楳率(CNS) T4規格(2丨0x297公放) A6 B6 3〇i2 Λ、發明説明(12 ) 在某些載劑(例如:在植物油中)的溶解度。已知nifedipine 是幾乎不能溶解於植物油中的。同時,由於植物油與驩囊 壁具有相容性,所以是棰佳的載剤,但是它的醮用受阻於 nifedipine的撖溶性。下列實驗証實了在植物性染料的效 應下,nifedipine在不同植物油中的溶解度以及其釋出均 權得改善。 藥物自鼷囊的釋出是依照美圃_典第二十二販的旋轉 嫌葉設備(rotating paddle equipment)測定的•以蒸皤 水作為溶解介質,測試時間十五分鏞,測試溫度為*氏 37 土 0.5度(每分鏟50轉)。其結果狳列於表二。 表 二 有效成分的釋出 (請先閱讀背面之注意事項再填辉本頁) .打· 經濟部中央標準局貝工消費合作社印製 作為溶劑的 植物油 装埔溶液中藥嫌素 的含量 (以質量計的百 分率,X ) 十五分鐘内自醪 囊繹出的有效成 分(以質悬計的 百分率,X) (要求:80 X ) 葫蘆油 - 82.30 鹄蘆油 1.5 92.40 葫蘆油 3.0 97.02 掙檝油 一 90.76 _____._14 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) •線. 203012 五、發明説明(13 ) 檸嫌油 1.5 95.37 檸檬油 3.0 100.14 橄欖油 - 86.38 橄横油 1.5 90.50 橄欖油 3.0 96.40 經濟部中央檁準局貝工消费合作杜印製 依照美困藥典第二十二販所載明的規定,nifedipine 的釋出必須至少逹到80X。由表二所列之數據可看出,自 使用了植物油作為溶劑(讁蘆油、檸樺油、橄攬油)的試樣 釋出的nifedipine超出此值甚多。此外,值得注意的是, 在有禁綠素存在時,nifedipine的釋出量明顯地大於只 使用相同的載劑而不使用任何植物性染料的。植物性染料 增進藥物的釋出不可能是可以預見的,所以逭項結果完全 令人驚奇。 本發明的進一步詳細内容可自下列實例獲知,逭些資 例並不限制本發明的範園。 實例一 装備一種具有下列組成的騵囊裝《料: 成份 含量,(以質量計之 百分率,X) (請先M續背面之汰意事ίιί·再填寫本页) •装. .打. -線.Nitro-nitroso other loading solution: Example 2 Mash capsule wall: Example 4 98.50 1.00 0.23 0.27 Packing solution: Example 1 Huan capsule wall: Example 5 98.00 0.90 0.24 0.86 Comparative example 1.8 0.4 0.8 (please read the back first Zhi Note Competition Item #Fill in this page) The Ministry of Economic Affairs, Bureau of Standards, EX Industry and Consumer Cooperation Co., Ltd. du printed the knowledge of the formation of the solution, according to the amount. The value of the soft country pharmacopoeia lightening agent should be in accordance with the requirements of the United States Pharmacopoeia 22 (USP XX II). The amount of nitro compounds should not exceed 2.0% in terms of quality eggs, while nitroso The quantity shall not exceed 0.5% in terms of quality. According to the data in Table 1, the decomposed products contained in the soft sacs prepared by the present invention are lower than the allowable degree. Note that even if only the plant-containing dyed capsules are contained in the filling, there is no alfalfa color in the sac wall. The incorporation of spurs can also meet the requirements of the 22nd US vendor. On the other hand, the wall of the lumbar sac does not contain anyone. It was surprisingly found that the method according to the present invention not only can prevent the invasion of light but also plant dyes can also increase the nifedipine 13 private paper "standard use rate. (CNS) T4 specifications (20 x 297 public) A6 B6 3〇i2 Λ, invention description (12) Solubility in certain carriers (for example: in vegetable oil). It is known that nifedipine is almost insoluble in vegetable oil. At the same time, due to the compatibility of vegetable oil and Huancao wall, it is a good carrier, but its use is hindered by the solubility of nifedipine. The following experiments confirmed that under the effect of plant-based dyes, the solubility and release of nifedipine in different vegetable oils can be improved. The release of the drug from the sachet is measured according to the rotating paddle equipment of Meipu _ Code 22nd Vendor • Using distilled water as the dissolution medium, the test time is 15 minutes, the test temperature is * 37 soil 0.5 degrees (50 shovel per minute). The results are listed in Table 2. Table 2 Release of active ingredients (please read the precautions on the back before filling in this page) Calculated percentage, X) Active ingredients extracted from the mash sac within 15 minutes (percentage based on mass suspension, X) (required: 80 X) Gourd oil-82.30 Moist oil 1.5 92.40 Gourd oil 3.0 97.02 Earned oil 1. 90.76 _____._ 14 This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210x297 mm) • Line. 203012 5. Description of the invention (13) Lime oil 1.5 95.37 Lemon oil 3.0 100.14 Olive oil-86.38 Olive oil 1.5 90.50 Olive oil 3.0 96.40 Printed by the Central Purchasing Agency of the Ministry of Economic Affairs and the Cooperative Consumer Printing Co., Ltd. According to the regulations stated in the 22nd Pharmacopoeia of the United States, the release of nifedipine must reach at least 80X. It can be seen from the data listed in Table 2 that the nifedipine released from the samples using vegetable oils as solvents (pascinia oil, birch oil, olive oil) exceeds this value by a large amount. In addition, it is worth noting that in the presence of forbidden chlorophyll, the amount of nifedipine released is significantly greater than that using only the same vehicle without using any vegetable dyes. It is impossible to predict the release of plant-based dyes from drugs, so the results of the previous item are completely surprising. Further details of the present invention can be obtained from the following examples. These examples do not limit the scope of the present invention. Example 1 Equipped with a zipper pack with the following composition: material content, (percentage by mass, X) (please continue with the first step on the back, then fill out this page) • Pack ... line.

Nifedipine 3.0 聚(乙烯化氣)-山梨糖酵IF -油酸酯 22.85 掸檬油 14.65 __ 15 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) ^03012 A6 B6 五、發明説明(14 ) 卵磷脂 葉綠素(親脂性) 57.00 2.50 經濟部中央標準局貝工消费合作社印製 100.00 製備方法:將聚(乙烯化氣)-一油酸山梨糖_加熱至 大約鑷氏70度,然後將nifedipine溶於其中。當溶解完成 後,趁熱将卵磷脂與親脂性禁綠素加入此溶液,然後將混 合物冷卻至室溫並將檸櫬油加入其中。如有痛要時,將溶 液通過塑驟篩網遇濾(孔徑:120號篩孔)。 實例二 製備具有下列組成之膠囊裝熵物: 成份 含量(以質量計之百分 率,X ) Nifedipine 2.80 聚(乙烯化氧)-山梨糖酵酐-油酸酯 82.50 葫蘆油 11.50 葉嫌素(親脂性) 3.20 100.00 製備方法:將聚(乙烯化氧)-山梨耱酵酐_油酸_加 熱至約攝氏70度,然後將nifedipine溶於其中。當溶解完 全後,將溶液冷卻至鑷氏45度,再将箱蘆油與親脂性藥綠 素加入其中。如有痛要時,將溶液通過塑顧篩網通濾(孔 T請先閱讀背面之注意事項再填寫本页) •打. .線· 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) <i〇3〇l2 A6 B6 五、發明説明(15 ) 徑:120號篩孔)。 實例三 裝備具有下列組成之0囊裝埔物: 成份 含最(以質量計之百分 率,X )Nifedipine 3.0 Poly (vinylidene gas) -Sorbitose IF-oleate 22.85 Smell oil 14.65 __ 15 This paper scale is applicable to China National Standard (CNS) A 4 specifications (210x297 mm) ^ 03012 A6 B6 V. Description of invention (14) Lecithin chlorophyll (lipophilic) 57.00 2.50 Printed by Beigong Consumer Cooperative of Central Bureau of Standards, Ministry of Economic Affairs 100.00 Preparation method: Heat poly (ethylene gas) -sorbic acid monooleate_ to approximately 70 degrees Celsius, then Dissolve nifedipine in it. When the dissolution is complete, add lecithin and lipophilic chlorophyllin to this solution while it is hot, then cool the mixture to room temperature and add citrus oil to it. In case of pain, filter the solution through a plastic screen (aperture: No. 120 mesh). Example 2 Preparation of capsule entropy with the following composition: Ingredient content (percentage by mass, X) Nifedipine 2.80 Poly (ethylene oxide) -sorbitan-oleate 82.50 Gourd oil 11.50 Ye Susu (lipophilic ) 3.20 100.00 Preparation method: Heat poly (ethylene oxide) -sorbican_oleic acid_ to about 70 degrees Celsius, and then dissolve nifedipine in it. When the dissolution is complete, cool the solution to 45 degrees Celsius, and then add the box of reed oil and lipophilic drug chlorophyll. If there is any pain, pass the solution through the plastic filter screen (please read the precautions on the back before filling the page) for the hole T. • Thread. · The paper size is applicable to the Chinese National Standard (CNS) A 4 specifications (210x297 Mm) < i〇3〇l2 A6 B6 V. Description of the invention (15) Diameter: No. 120 mesh). Example 3 The equipment has the following composition of 0 capsules: Ingredients Containing the most (percentage by mass, X)

Nifedipine Carbovax 300 檸樣油 葉緣素(親水性) 4.00 88.00 3.00 5.00 經濟部中央標準局員工消費合作杜印製 100.00 製備方法:將Carbowax 300加熱至攝氏60度,然後將 Nifedipine溶解於其中。當溶解完成後,將溶液冷卻至鑷 氏25至30度,再將親水性葉錄素與擰檬油加至其中。如有 需要時,將溶液通過塑腰篩網(孔徑:120號篩孔)過濾。 實例四 製備具有下列組成之謬囊壁: 成份 含Μ(以質量計之百分 率,X ) 明驂 50.00 甘油 27.00 ------ 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) ^03012 A6 B6 五、發明説明(16 ) 山梨糖酵70¾ 6.00 蒸蹓水 17.00 100.00 製備方法:將水加熱至攝氏80度,再將山梨糖酵與甘 油加入其中。然後在劇烈攪拌下將明睡加入此混合物並繼 鑲於真空下《拌,直至此混合物變為半透明蛛蜜狀物質為 止。將此物質以就其本身而論的已知方法,以機械製迪成 為醪囊。 實例五 製備具有下列組成之醪囊壁: 成份 含董(以質曇計之百分 率,* ) 【請先閱讀背面之注意事項再填寫本頁) •裝· 明膠 甘油 防腐劑 葉錄素(親水性) 蒸晡水 45.00 36.300.20 0.50 18.00 .線. 經濟部中央標率局貝工消费合作杜印製 100.00 製備方法:將水加熱至鑷氏80度,並將防腐_溶解於 其中。然後将甘油加入此溶液,在劇烈的攪拌下將明謬加 入其中。在抽真空下邋鑛《拌,直至此混合物變為半透明 ____18_ 本紙張尺度適用中國國家標準(CNS)甲4規格(210x29/公釐) 203012 A6 ___B6 五、發明説明(17 ) 的蛛蜜狀物質為止。将葉嫌素單獮地溶解於小量的水中, 再將水溶液與冷至攝氏60度的上述蜂蜜狀物質相混合。然 後將此所得之物質以就其本身而論的已知方法以機械製迪 成為謬囊。 實例六 製備具有下列成分的騵囊壁: 成份 含量(以質董計之百分 率,X ) (請先Μ讀背面之U意事叫再填^4頁) 明謬 甘油 聚乙烯基吡咯烷酮 葉嫌素(親水性) 蒸脯水 45.00 37.00 5.001.0012.00 經濟部中央標準局貝工消費合作社印製 100.00 製備方法,將水加熱至攝氏80度,再將聚乙烯基吡咯 烷酮溶解於其中,然後将甘油加至此溶液。其次在遽鑛地 劇烈攪拌下將明睡加入此混合物。再於抽與空下》拌此物 質,直至其轉變為半透明之蛛蜜狀産物為止。將窠嫌素單 獨地溶解於小量水中,令此水溶液與冷至鑷氏60度的上述 蜂萑狀物霣相混合。最後將所得的産物以就其本身而綸的 已知方法以機械製造成為醪囊。 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐)Nifedipine Carbovax 300 Lemon-like oil Phyllanthin (hydrophilic) 4.00 88.00 3.00 5.00 DuPont Printing by Employee Consumer Cooperation, Central Bureau of Standards, Ministry of Economic Affairs 100.00 Preparation: Heat Carbowax 300 to 60 degrees Celsius, and then dissolve Nifedipine in it. When the dissolution is complete, cool the solution to 25 to 30 degrees tweezers, and add the hydrophilic phytohormones and lemon oil to it. If necessary, filter the solution through a plastic waist screen (aperture: No. 120 mesh). Example 4 Preparation of a wall of absurd bladders with the following composition: Ingredients containing Μ (percentage by mass, X) Mingji 50.00 Glycerin 27.00 ------ This paper scale is applicable to China National Standard (CNS) A 4 specifications (210x297 %) ^ 03012 A6 B6 V. Description of the invention (16) Sorbushase 70¾ 6.00 Steamed water 17.00 100.00 Preparation method: Heat the water to 80 degrees Celsius, then add sorbitan and glycerin. Then add bright sleep to this mixture under vigorous stirring and continue to set under vacuum until the mixture becomes a translucent spider-like substance. This material is mechanically made into a mash in a known way for itself. Example 5 Preparation of mash capsule wall with the following composition: Ingredients containing Dong (percentage by mass, *) [Please read the precautions on the back before filling out this page) • Pack · Gelatin glycerin preservative phytolactin (hydrophilic) ) Distilled water 45.00 36.300.20 0.50 18.00. Line. Central Printing Bureau of Ministry of Economic Affairs, Beigong Consumer Co., Ltd. Duprint 100.00 Preparation method: Heat the water to 80 degrees Celsius, and dissolve the antiseptic _ in it. Glycerin is then added to this solution, and ming yang is added to it with vigorous stirring. Under vacuum, sloppy ore "mix until the mixture becomes translucent ____18_ This paper scale is applicable to China National Standard (CNS) A 4 specifications (210x29 / mm) 203012 A6 ___B6 V. The description of the spider honey (17) Like substance. Dissolve phylloxanthin alone in a small amount of water, and then mix the aqueous solution with the above-mentioned honey-like substance cooled to 60 degrees Celsius. The resulting material is then made mechanically by a known method in its own right as a fallacy. Example 6 Preparation of the wall of the pharyngeal sac with the following components: Content of the component (percentage based on quality, X) (please read the U on the back and fill in page ^ 4) Ming glycerin polyvinylpyrrolidone (Hydrophilic) Steamed preserved water 45.00 37.00 5.001.0012.00 Printed 100.00 by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economy. Preparation method, heat the water to 80 degrees Celsius, then dissolve polyvinylpyrrolidone in it, and then add glycerin here Solution. Secondly, under the vigorous agitation of the Yunkuang Mine, add Mingsleep to this mixture. Then mix it with the pumping and emptying until it turns into a translucent spider honey product. Separately dissolve hormonin in a small amount of water, and mix this aqueous solution with the above-mentioned bee-weed that has been cooled to 60 degrees Celsius. Finally, the resulting product is mechanically manufactured into a mash in a known manner that is inherent in itself. The size of this paper applies to China National Standard (CNS) Grade 4 (210x297 mm)

Claims (1)

正正正正 0000 六、申請專利範園 (請先閲讀背面之注意攀項再填寫本頁) 1.—種具光安定性之固讎蕖學组成物,其供含有一種感 光性及邐擇性地幾乎不溶於水的有效成分速同習用的截瘌 及/或_肋_之軟醪囊,其中所述的组成物為含有作為有 效成分之Nifedipine及含有蕖癱素於裝燠溶液中,且選擇 性地含藥鎌索於_囊壁中。 2- 一種製迪如申請専利範蘭第1項之固體藥學組成物之 方法,其中,包括將蕖嫌索混入此组成物。 3. 如申讅専利範鼷第2項之方法,其中,包括:就组成 物餹質量計,蕖鏵素之用量為百分之0.1至10之量。 4. 如申_專利範園第2項之方法,其中,包括使用 Nifedipine作為幾乎不溶於水及/或想光性有效成分。 5. 如申請専利範圃第2項之方法,其中,包括製傭軟騮 囊、釀Η、糖衣蕖九或磺醪囊為固鱺藥學組成物。 6. 如申讅專利«函第5項之方法,其中,包括裂備軟謬 囊為固體藥學組成物。 7. 如申讅専利範園第2項之方法,其中,包括將以質量 為百分之0.1至10的葉嫌素混入膠囊装*物及/或臞囊蟹 中。 經濟部中央標準屬S工消费合作杜印製 8. 如申讅専利«園第6項之方法,其中包括將以質量計 為百分之1至10,合意地是百分之1至5,持別合意地是百 分之1.5至3.5的親臑性蕖鑤素混入軟謬囊之裝填物中。 9. 如申謫専利範臞第6項之方法,其中包括將以質置計 為百分之0.5至10,合意地是百分之1至7,特別合意地是 百分之1.5至5的親水性藥嫌索混入軟臞囊之裝«物中。 -20 - 本紙張尺度適用中國國家櫺準(CNS>甲4規格(210 X 297公釐) 81.9,10,000 ^03012 A7 B7 C7 D7 _ 六、申請專利範团 一 I (請先閱讀背面之注意.拿項再填寫本茛) 10. 如申讅専利鮪圓第6項之方法,其中包括使用以質量 計為百分之1至7、合意地是百分之1.5至5的藥》素及習 用的載_輿_肋_ -合意地是植物油輿芳香油或非離子型 表面活性_及芳番阐-以製備軟騵囊之裝填物。 11. 如申謫専利範蘭第7項之方法,其中包括將以霣董計 為百分之0.1至5,合意地是百分之〇.2至3,特別合意地是 百分之0· 3至1.5的藥錄索混入黷囊壁。 12. 如申謫専利範園第2項之方法,其中包括装填一種含 有下列成分之組合物至騮囊中:以霣量計百分之2至5之 Hifedipine, —種非難子型表面活性爾,及以質量計百分 之0.5至10,合意地是百分之1至7,特別合意的是百分之 1.5至5的葉嫌素,此膠囊具有一包含明醪基霣增塑爾-合意地是丙三酵或山梨_酵,及钃襻性地含一種防腐M, 訂- 及遘擇性地含以質置計百分之0.1至5,合意地為百分之0.2 至3 ,特別合意地為百分之0.3至1.5之葉嫌素。 經濟部中央標準扃工消费合作杜印製 13. 妁申讅専利範第12項之方法,包括將含有下列成分 之组成物裝《進入具有含丙三酵及S擇性地含以質量計為 百分之0.3至1.5藥嫌素的明0基霣壁的醪囊:以霣量計為 百分之2至5的(Nifedipine,—種蠹自由葵花油、鷂蘆油、 檝欖油及擰様油構成之群的油,一種聚(乙烯化氣)-山梨 酵酐脂肪醎釀-合意地為聚(乙烯化氣)-山梨糖酵酐-油 酸_,或聚乙二酵及以質Λ計為百分之1.5至3.5之藥綠素 -21 - 81.9.10,000 本紙張尺度適用中國國家櫺準(CNS)甲4規格(210 X 297公釐)Zhengzhengzheng 0000 6. Applying for a patent fan garden (please read the notes on the back and then fill in this page) 1.—A kind of light-stabilized solid chrysanthemum composition, which contains a kind of photosensitivity and selection The active ingredient that is practically insoluble in water is the same as the customary truncated and / or ribbed soft mash capsules, wherein the composition is Nifedipine containing active ingredient and containing paracetamol in the container solution. And selectively contain the drug Sisi in the wall of the cyst. 2- A method for preparing a solid pharmaceutical composition according to Item 1 of Difanlan, which includes mixing the suspicion into this composition. 3. For example, if the method of item 2 of Shenli Fanfan is included, it includes: in terms of the mass of the composition, the amount of valerin is 0.1 to 10 percent. 4. For example, the method of item 2 of the _Patent Fanyuan, which includes the use of Nifedipine as an almost insoluble and / or photoactive active ingredient. 5. For example, the method of applying for item 2 of the Lifanpu, which includes the production of soft sacs, boiled H, sugar-coated jiujiu or saccharomyces sac as solid pharmacy composition. 6. For example, the method of claim 5 of the «Letter of Patent Application>, which includes the preparation of a soft pharmaceutical capsule as a solid pharmaceutical composition. 7. The method as described in item 2 of Shenfan Fanyuan, which includes mixing 0.1% to 10% of phytoalexin into capsules and / or sac crab. The Central Standard of the Ministry of Economic Affairs is produced by S-Industry and Consumer Cooperation Co., Ltd. 8. For example, the method of item 6 of the «Park», which will include 1 to 10 percent by mass, desirably 1 to 5 percent, It is unfavorable that 1.5% to 3.5% of the prolactin is mixed into the filling of the soft pouch. 9. For example, the method of item 6 of the application plan, which includes the quality of 0.5 to 10 percent, desirably 1 to 7 percent, and particularly desirably 1.5 to 5 percent Hydrophilic drug suspects are mixed into the soft bursa. -20-This paper scale is applicable to the Chinese National Standard (CNS> A4 specifications (210 X 297 mm) 81.9,10,000 ^ 03012 A7 B7 C7 D7 _ 6. Apply for a patent model group I (please read the note on the back first Take the item and fill in this ranunculus) 10. For example, if you apply for the method of item 6 of the Tuna Circle, it includes the use of medicines with a quality of 1 to 7 percent and desirably 1.5 to 5 percent.的 载 _ 予 _rib_ -Desirably vegetable oil and aromatic oil or non-ionic surface active_ and Fangfan explain- to prepare the filling of soft hull. 11. As in the method of item 7 of Shenfanlifanlan, This includes mixing 0.1 to 5 percent of Yuan Dong, desirably 0.2 to 3 percent, and particularly desirably 0.3 to 1.5 percent, into the wall of the purgular sac. 12. For example, the method of item 2 of Shenfanli Fanyuan includes filling a composition containing the following ingredients into the episac: Hifedipine, 2 to 5 percent by weight, a non-difficult surface active agent, and 0.5% to 10% by mass, desirably 1 to 7%, and particularly desirably 1.5 to 5% phytoalexin, this capsule has a packet Contains melamine base plasticizer-desirably glycerin or sorbic acid yeast, and tincture contains a kind of antiseptic M, ordered-and optionally contains 0.1 to 5, percent by quality, desirable The area is 0.2 to 3 percent, and particularly desirable is 0.3 to 1.5 percent. The central government ’s Ministry of Economic Affairs ’Central Standards Consumer Cooperation Co., Ltd. Du Duan 13. The method of item 12 in the application of the law, including The composition containing the following ingredients is loaded into "mash capsules containing glycerol-containing three enzymes and S selectively containing 0.3 to 1.5% of the analyte by mass as the base of the 0-basic wall: a percentage based on the amount of corn Part 2 to 5 (Nifedipine, — a group of oils composed of free sunflower oil, hawthorn oil, sylvestris oil, and koji oil, a type of poly (ethylene gas) -sorbitan fat-fat brewing-desirably Poly (ethylene gas)-sorbitan-oleic acid_, or poly-glyoxygenase and medicinal chlorophyll -21-81.9.10,000 in terms of mass Λ-81.9.10,000 This paper size is applicable to China Standard (CNS) A 4 specifications (210 X 297 mm)
TW080105605A 1990-07-20 1991-07-19 TW203012B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU904564A HUT59592A (en) 1990-07-20 1990-07-20 Process for the preparation of solid medical products

Publications (1)

Publication Number Publication Date
TW203012B true TW203012B (en) 1993-04-01

Family

ID=10968329

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080105605A TW203012B (en) 1990-07-20 1991-07-19

Country Status (22)

Country Link
JP (1) JPH04253924A (en)
KR (1) KR920002162A (en)
BE (1) BE1006829A3 (en)
CA (1) CA2047482A1 (en)
CH (1) CH681960A5 (en)
CY (1) CY1840A (en)
CZ (1) CZ280064B6 (en)
DE (1) DE4124081A1 (en)
DK (1) DK137591A (en)
ES (1) ES2039177B1 (en)
FI (1) FI913493A (en)
FR (1) FR2664814B1 (en)
GB (1) GB2246072B (en)
GR (1) GR1002175B (en)
HU (1) HUT59592A (en)
IL (1) IL98894A0 (en)
IT (1) IT1250681B (en)
NL (1) NL9101268A (en)
SE (1) SE9102160L (en)
TW (1) TW203012B (en)
YU (1) YU47573B (en)
ZA (1) ZA915677B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411115D0 (en) * 1994-06-03 1994-07-27 Secr Defence Stabilisation of photosensitive material
RU2109510C1 (en) * 1995-04-24 1998-04-27 Пфайзер Инк. Method of inhibition, tablet and capsule
DE19912623A1 (en) * 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Process for increasing the stability when storing and / or using light-sensitive therapeutic systems or their components
JP3549522B1 (en) * 2003-10-24 2004-08-04 日清ファルマ株式会社 Coenzyme Q10-containing capsule
WO2010038771A1 (en) * 2008-09-30 2010-04-08 中外製薬株式会社 Light-stabilized pharmaceutical composition
CA2968861C (en) 2017-05-30 2022-10-11 University Of Saskatchewan Topical nifedipine formulations and uses thereof
KR200489660Y1 (en) * 2018-02-09 2019-07-19 김순희 Putting Exerciser

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55127448A (en) * 1979-03-23 1980-10-02 Chugai Pharmaceut Co Ltd Gelatin coating
JPS6043046B2 (en) * 1979-04-24 1985-09-26 パ−ク・デ−ビス・エンド・コンパニ− gelatin capsules
JPS55161863A (en) * 1979-06-06 1980-12-16 Paaku Deebisu Kk Colored gelatin capsule
ATE33348T1 (en) * 1983-11-30 1988-04-15 Siegfried Ag CORONAR THERAPY IN THE FORM OF SOFT GELATIN CAPSULES.
JPS61225109A (en) * 1985-03-29 1986-10-06 Shiseido Co Ltd Caramel-containing composition
DE3526546A1 (en) * 1985-07-25 1987-01-29 Scherer Gmbh R P LIGHT-RESISTANT OPAKED GELATINE CAPSULES AND METHOD FOR THE PRODUCTION THEREOF
DE3532129A1 (en) * 1985-09-10 1987-03-12 Bayer Ag GELATINE CONTAINING SS CAROTINE
US4689233A (en) * 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
DE3682208D1 (en) * 1986-12-18 1991-11-28 Kurt Heinz Bauer STABILIZED NIFEDIPINE CONCENTRATE AGAINST THE INFLUENCE OF LIGHT AND METHOD FOR THE PRODUCTION THEREOF.
JPS63215641A (en) * 1987-03-05 1988-09-08 Toyo Jozo Co Ltd Gelatin film composition
JPH01218573A (en) * 1988-02-25 1989-08-31 Yoshio Tanaka Dunaliella algae-containing solid food and production thereof

Also Published As

Publication number Publication date
CY1840A (en) 1996-03-08
GB2246072A (en) 1992-01-22
SE9102160D0 (en) 1991-07-10
IL98894A0 (en) 1992-07-15
ITMI912002A0 (en) 1991-07-19
IT1250681B (en) 1995-04-21
BE1006829A3 (en) 1995-01-03
CA2047482A1 (en) 1992-01-21
ITMI912002A1 (en) 1993-01-19
FR2664814B1 (en) 1995-05-24
DK137591D0 (en) 1991-07-19
GR1002175B (en) 1996-03-07
JPH04253924A (en) 1992-09-09
NL9101268A (en) 1992-02-17
ES2039177A1 (en) 1993-09-01
SE9102160L (en) 1992-01-21
GB9115693D0 (en) 1991-09-04
CS222291A3 (en) 1992-02-19
YU47573B (en) 1995-10-03
FI913493A0 (en) 1991-07-19
FI913493A (en) 1992-01-21
GB2246072B (en) 1994-06-15
ES2039177B1 (en) 1994-03-16
HU904564D0 (en) 1990-12-28
FR2664814A1 (en) 1992-01-24
KR920002162A (en) 1992-02-28
HUT59592A (en) 1992-06-29
CZ280064B6 (en) 1995-10-18
GR910100319A (en) 1992-08-26
DE4124081A1 (en) 1992-01-23
ZA915677B (en) 1993-03-31
DK137591A (en) 1992-01-21
CH681960A5 (en) 1993-06-30
YU127191A (en) 1994-05-10

Similar Documents

Publication Publication Date Title
US4070494A (en) Enteral pharmaceutical compositions
EP0277459B1 (en) Sustained release drug
JP2000514406A (en) Enteric coating consisting of alginic acid for oral administration
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
DE69723248T2 (en) COMPOSITIONS FOR SYMPATHOMIMETIC AMINE SALT
CH679011A5 (en)
US8420700B1 (en) Tamper resistant lipid-based oral dosage form for sympathomimetic amines
TW203012B (en)
NZ270439A (en) Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
CA2137764C (en) Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride
FR2508313A1 (en) NOVEL PHARMACEUTICAL FORMULATIONS BASED ON Rye ERGAL ALKALOIDS AND THEIR PREPARATION
NO303669B1 (en) Process for preparing a tablet or preparation
TWI260224B (en) Pharmaceutical compositions for the treatment of tumor diseases
TWI286072B (en) Sleeping medicine formed by coating solid
DE10392718T5 (en) A pharmaceutical formulation in a drug delivery system and method of making the same
EP0523153B1 (en) Oleaginous capsule of ketoprofen
EA015440B1 (en) Solid dosage form containing clopidogrel hydrogenesulphate of polymorph form 1
JPS6140647B2 (en)
EP1137653A1 (en) Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same
KR100201907B1 (en) A softcapsule containing biphenyldimethyldicarboxylate (pmc) solution
MXPA03002013A (en) Tablets containing epinastine manufactured by direct compression.
KR100201906B1 (en) A softcapsule having solubilized famotidine
US3361627A (en) Phenothiazine compositions
RU2200558C1 (en) Medicinal agent comprising finasteride
CN115957194A (en) Solvent system for content in cold soft capsule and cold soft capsule